Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROCEADE PanTumor NSCLC substudy of M9140 in advanced CEACAM5-expressing non-small cell lung cancer
2024-517818-15-00Phase 2Authorised
- Sponsor
- Merck KGaA
- Start
- Jun 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 10
01
Overview
Phase 2, open-label trial of precemtabart tocentecan in non-small cell lung cancer (NSCLC) (2 arms), sponsored by Merck KGaA. Primary endpoint: Objective response. Planned start Jun 2025; status: authorised.
02
Drugs
precemtabart tocentecan
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-517818-15-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517818-15-00.